Key Capital Corporation

Key Capital Corporation is a diversified public holding company that has pivoted its primary focus toward the life sciences and financial technology sectors. The company's life sciences division is centered on the development of Targeted Hyperthermia Therapy (THT), a proprietary non-invasive oncology platform that uses nanoparticles and radiofrequency to treat solid tumors. Beyond oncology, Key Capital is involved in exploring regenerative medicine solutions for neurological conditions. The company operates as an incubator and developer, seeking to advance these technologies through clinical stages or strategic partnerships. While maintaining interests in natural resources, its current growth strategy is heavily weighted toward high-tech medical innovations.